Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
Line 427: Line 427:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Infection'''  
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! rowspan="2" align="center" style="background:#DCDCDC;" + |'''Viral infections'''
!
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
!
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Infection'''  
! align="center" style="background:#DCDCDC;" + |'''Viral infections such as:'''


rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus
!rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus
!
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 478: Line 453:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!
!'''HIV'''
!'''HIV'''  
!
!
!
* Direct toxicity to megakaryocytes
* Direct toxicity to megakaryocytes
Line 506: Line 479:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
! rowspan="3" |Bacterial infections
!'''Sepsis'''
!'''Sepsis'''
!
!Direct bone marrow suppression
!Direct bone marrow suppression
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 531: Line 503:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
!Helicobacter pylori
!Helicobacter pylori
!
!Immune thrombocytopenia
!Immune thrombocytopenia
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 556: Line 526:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
!leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections
!leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections
!
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 581: Line 549:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
! rowspan="2" |'''Intracellular parasites'''
! rowspan="2" |'''Intracellular parasites'''
!Malaria
!Malaria
Line 606: Line 573:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
!Babesiosis  
!Babesiosis  
|
|
Line 630: Line 596:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Medications
! rowspan="6" |Medications/toxicity
!'''Drug-induced immune thrombocytopenia'''
!'''Drug-induced immune thrombocytopenia'''
!
!
Line 665: Line 631:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
!'''Heparin-induced thrombocytopenia'''  
!'''Heparin-induced thrombocytopenia'''  
!
!
Line 690: Line 655:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
!'''Cytotoxic chemotherapy'''
!'''Cytotoxic chemotherapy'''
!
!
Line 715: Line 679:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
!'''Radiation therapy'''
!'''Radiation therapy'''
!
!
Line 740: Line 703:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
!OTC agents
!OTC agents
!Quinine-containing beverages
!Quinine-containing beverages
Line 765: Line 727:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |
!
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
!
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
|-
!
! align="center" style="background:#DCDCDC;" + |'''Alcohol'''  
! align="center" style="background:#DCDCDC;" + |'''Alcohol'''  
!
!
Line 1,034: Line 971:
!
!
|-
|-
!'''Rheumatologic/autoimmune disorders'''
!Systemic lupus erythematosus (SLE)
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!
!Antiphospholipid syndrome (APS)
!
!autoantibody-mediated syndrome
!
!
!
!
Line 1,059: Line 1,021:
!
!
|-
|-
!
!Felty's syndrome
!
!splenomegaly
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
! rowspan="3" |vascular
!giant capillary hemangioma,
!
!platelet destruction
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!large aortic aneurysms,
!
!platelet destruction
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!cardiopulmonary bypass
!
!platelet destruction
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!
!Post-transfusion purpura
!
!immune-mediated platelet destruction
!
!
!
!

Revision as of 18:42, 7 August 2018

Thrombocytopenia Differential Diagnosis

Differentiating the diseases that can cause thrombocytopenia:

Category Condition Clinical manifestations Para−clinical findings Gold standard Associated findings
Symptoms Signs
Lab Findings Imaging
Severity Fever Bleeding BP Other CBC PBS Coagulopathy
Mechanism
Infectious diseases Gestational thrombocytopenia
Chronic liver disease
portal hypertension
Hypersplenism
Immune thrombocytopenia Antibody-mediated platelet destruction Moderate to severe - Diagnosis of exclusion
Congenital platelet disorders MYH-9 related disorders
Bernard-Soulier syndrome
Gray platelet syndrome
Wiskott-Aldrich syndrome
Thrombocytopenia with absent radius (TAR) syndrome
Alport syndrome
Von Willebrand disease
Infection Viral infections rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus
HIV
  • Direct toxicity to megakaryocytes
  • An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT)
  • Secondary opportunistic infections
Bacterial infections Sepsis Direct bone marrow suppression
Helicobacter pylori Immune thrombocytopenia
leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections
Intracellular parasites Malaria
Babesiosis
Medications/toxicity Drug-induced immune thrombocytopenia
  • Antibiotics
    • Sulfonamides
    • Ampicillin
    • Piperacillin
    • Vancomycin
    • Rifampin
  • Older antiepileptic agents
    • carbamazepine
    • Phenytoin
  • Quinine
Occurrence of drug-dependent, platelet-reactive antibodies
Heparin-induced thrombocytopenia
Cytotoxic chemotherapy
Radiation therapy Predictable, dose-dependent myelosuppression
OTC agents Quinine-containing beverages
Alcohol
Malignancy
Nutrient deficiencies folate, vitamin B12, copper an autoimmune mechanism Mild
Thrombotic microangiopathy (TMA) Thrombotic thrombocytopenic purpura (TTP)
Hemolytic uremic syndrome (HUS)
Drug-induced TMA (DITMA)
Bone marrow disorders Myelodysplastic syndromes
Aplastic anemia
Acute leukemia
Paroxysmal nocturnal hemoglobinuria (PNH)
Rheumatologic/autoimmune disorders Systemic lupus erythematosus (SLE)
Antiphospholipid syndrome (APS) autoantibody-mediated syndrome
Felty's syndrome splenomegaly
vascular giant capillary hemangioma, platelet destruction
large aortic aneurysms, platelet destruction
cardiopulmonary bypass platelet destruction
Post-transfusion purpura immune-mediated platelet destruction